Title : The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.

Pub. Date : 2017 Nov 27

PMID : 29186917






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Lazabemide is a monoamine oxidase (MAO)-B inhibitor, a class of compounds that slows the depletion of dopamine stores in Parkinson"s disease and elevates dopamine levels produced by exogenously administered l-dopa. Levodopa monoamine oxidase B Mus musculus